Infinium Pharmachem Limited
The INSIDE of APIs

Corporate Office Address :
Suite # 205, Sigma Prime, Nr. Sardar Patel Statue
Vallabh Vidhyanagar-388120, Gujarat, India
Info@infiniumpharmachem.com
+91-2692-238849, 238850
www.infiniumpharmachem.com

R.O. & Factory Address :
Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,
Gujarat, India Tel/fax : +91-2697-234987, 296000
CIN NO : L24231GJ2003PLC043218

November 18, 2026

TO,
NSE LIMITED
EXCHANGE PLAZA, 5th FLOOR,
PLOT NO. C/1, G BLOCK, BANDRA-KURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.
SYMBOL: INFINIUM

Dear Sir/Madam,

Sub: Intimation of In-Principle Approval received for Migration of Equity Shares from NSE SME Platform (EMERGE) to NSE Main Board

With reference to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that Infinium Pharmachem Limited (the "Company") has received "In-Principle approval" from the National Stock Exchange of India Limited for Migration of its equity shares from NSE SME Platform (EMERGE) to NSE Main Board vide its In-Principle approval letter No. NSE/LIST/317 dated November 18, 2026.

Please find enclosed herewith a copy of the In-Principle approval letter of NSE.

Kindly take the same in your records.

Thanking You,

Yours Faithfully,

For Infinium Pharmachem Limited

KUNJ ANJAYKUMAR DESAI

Digitally signed by KUNJ ANJAYKUMAR DESAI
Date: 2026.11.18 17:38:25 +05'30'

Kunj Desai
Company Secretary & Compliance Officer

Encl: As above

Ref: NSE/LIST/317 November 18, 2026

The Company Secretary
Infinium Pharmachem Limited

Dear Sir/Madam,

Re: In-principle approval for migration of trading in the equity shares of the company from SME Platform (EMERGE) to Main Board.

We are in receipt of your application regarding in-principle approval for migration of trading in the 15583120 equity shares of Rs. 10/-each of the company from SME Platform (EMERGE) to Main Board in terms of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018.

In this regard, the Exchange is pleased to grant in-principle approval for proposed migration of trading in the equity shares of the company from SME Platform (EMERGE) to Main Board.

Kindly note that the Exchange will issue final approval for migration of trading in the equity shares of the company from SME Platform (EMERGE) to Main Board on submission of listing application including equity listing agreement.

"Kindly note, this Exchange letter should not be construed as approval under any other Act /Regulation/rule/bye laws (except as referred above) for which the Company may be required to obtain approval from other department(s) of the Exchange. The Company is requested to separately take up matter with the concerned departments for approval, if any."

The Exchange reserves its right to withdraw its in-principle approval at a later stage if the information submitted to the Exchange is found to be incomplete/incorrect/misleading/false or in contravention of any Rules, Bye-laws and Regulations of the Exchange, SEBI (LODR) Regulations, 2015, Guidelines/ Regulations issued by statutory authorities, etc.

This In-principle approval is valid for a period of 45 days from the date of issuance of this letter.

Yours faithfully,
For National Stock Exchange of India Limited

Ankita Gupta
Manager

The National Stock Exchange of India (NSE) has announced the launch of NEAPS mobile application. The app can be downloaded from the App Store/ Play store with the name "NEAPS APP"

This Document is Digitally Signed

Signed by: Ankita Gupta
Date: Wed, Nov 18, 2026 15:27:39 IST
Location: NSE